FibroScan (VCTE): When to Order This Test

What Is FibroScan (VCTE) and How Does It Work?

FibroScan uses a probe placed on the right intercostal space to transmit a low-frequency vibration (50 Hz) into the liver. The device tracks the speed of the resulting shear wave: stiffer tissue transmits the wave faster, producing a higher kilopascal (kPa) reading. A simultaneous ultrasound attenuation measurement generates the controlled attenuation parameter (CAP), which quantifies hepatic fat.

The test replaced liver biopsy as the first-line fibrosis assessment tool in most hepatology and primary care settings over the past decade. A 2019 meta-analysis published in Gastroenterology (N=5,735) reported that VCTE had a pooled sensitivity of 87% and specificity of 82% for detecting significant fibrosis (F≥2), with an AUROC of 0.88 [1]. For cirrhosis (F4), sensitivity rose to 92% with specificity of 87% [1].

The exam takes about 10 minutes. Patients lie supine with the right arm raised. The operator obtains 10 valid measurements; the device reports a median value and an interquartile range (IQR). A valid study requires an IQR-to-median ratio of 30% or less and a success rate above 60% [2]. No sedation, no needles, no radiation. Results are available immediately.

When Should You Order a FibroScan?

The short answer: order a FibroScan whenever you need to quantify liver fibrosis or steatosis without performing a biopsy. The 2023 AASLD Practice Guidance on MASLD explicitly recommends VCTE as a first-line non-invasive test (NIT) for fibrosis staging in patients with suspected or confirmed steatotic liver disease [3].

Specific clinical scenarios that warrant ordering:

1. MASLD screening in high-risk metabolic populations. The American Gastroenterological Association (AGA) 2023 Clinical Practice Update recommends using VCTE in adults with type 2 diabetes, obesity (BMI ≥30), or metabolic syndrome who have elevated FIB-4 scores (≥1.3) [4]. This two-step pathway (FIB-4 first, then VCTE) avoids unnecessary specialist referrals.

2. Staging fibrosis before initiating resmetirom (Rezdiffra). The FDA approved resmetirom in March 2024 for non-cirrhotic MASH with moderate to advanced fibrosis (F2-F3). The prescribing label requires documented fibrosis staging [5]. VCTE with an LSM of 8.0 to 13.9 kPa (F2-F3 range in MASLD) satisfies this requirement without biopsy in many clinical protocols.

3. Chronic hepatitis B or C monitoring. AASLD guidelines recommend VCTE for baseline fibrosis assessment and longitudinal monitoring in chronic viral hepatitis [6]. Post-SVR (sustained virologic response) patients with prior advanced fibrosis should have annual or biennial VCTE to confirm regression or detect progression.

4. Alcohol-related liver disease (ALD). The ACG 2020 Clinical Guideline on ALD recommends VCTE for fibrosis assessment, noting that LSM cutoffs differ slightly from MASLD (an LSM ≥12.5 kPa corresponds to F4 in ALD vs. ≥13.6 kPa in MASLD) [7].

5. Pre-bariatric surgery liver assessment. Many bariatric programs now include VCTE to identify occult cirrhosis before surgery, which may alter the surgical approach or require hepatology co-management.

6. Serial monitoring of known fibrosis. VCTE is repeatable, radiation-free, and inexpensive relative to MRI elastography. Repeat testing at 12- to 24-month intervals tracks disease trajectory in patients with established MASLD or viral hepatitis.

How to Interpret FibroScan Results: Normal Ranges and Fibrosis Staging

A normal liver stiffness measurement falls below 7.0 kPa. Anything above that threshold requires clinical context, because the kPa cutoffs shift depending on the underlying liver disease.

MASLD/MASH fibrosis cutoffs (AASLD 2023):

• F0-F1 (no significant fibrosis): <8.0 kPa
• F2 (significant fibrosis): 8.0 to 9.6 kPa
• F3 (advanced fibrosis): 9.7 to 13.5 kPa
• F4 (cirrhosis): ≥13.6 kPa

Chronic hepatitis C cutoffs:

• F0-F1: <7.1 kPa
• F2: 7.1 to 9.4 kPa
• F3: 9.5 to 12.4 kPa
• F4: ≥12.5 kPa

CAP score interpretation for steatosis:

• S0 (no steatosis): <238 dB/m
• S1 (mild, 5-33% fat): 238 to 259 dB/m
• S2 (moderate, 34-66% fat): 260 to 292 dB/m
• S3 (severe, >66% fat): ≥293 dB/m

These thresholds come from a 2021 individual patient data meta-analysis in Hepatology (N=3,830) that validated CAP against histology [8]. The diagnostic accuracy for S≥1 was modest (AUROC 0.82), which means CAP works best as a screening tool rather than a precision grading instrument.

"A single FibroScan value should never be interpreted in isolation," notes the AASLD 2023 guidance document. "Clinicians should integrate VCTE results with serum-based NITs, clinical context, and imaging findings to make staging decisions" [3].

The Two-Step Fibrosis Screening Pathway: FIB-4 Then FibroScan

Most guidelines now endorse a sequential approach. Start with the FIB-4 index (a free calculation using age, AST, ALT, and platelet count), then escalate to VCTE when FIB-4 suggests possible fibrosis.

The AGA pathway works like this: calculate FIB-4 in any at-risk patient. A score below 1.3 rules out advanced fibrosis with a negative predictive value above 90% [4]. A score between 1.3 and 2.67 sits in the indeterminate zone, and these patients need a FibroScan. A score above 2.67 strongly suggests advanced fibrosis and warrants direct hepatology referral, though VCTE still adds value for baseline quantification.

In a 2022 prospective cohort published in The Lancet Gastroenterology & Hepatology (N=1,046), this sequential strategy correctly classified 78% of patients without requiring liver biopsy, while missing only 4% of patients with F3-F4 disease [9]. The approach reduced unnecessary specialist referrals by 54% compared with FIB-4 alone.

This pathway matters for primary care. Over 80 million U.S. adults have MASLD according to 2023 prevalence estimates [10]. Universal FibroScan screening is neither feasible nor cost-effective. But targeted VCTE after an indeterminate or high FIB-4 catches the patients who need treatment while keeping the number of scans manageable.

What Makes a FibroScan Result Unreliable?

Several factors can produce falsely elevated or uninterpretable readings. Knowing these pitfalls prevents misdiagnosis.

Falsely elevated LSM (overestimation of fibrosis):

• Eating within 2 hours of the test. Food intake increases hepatic blood flow and can raise LSM by 1 to 2 kPa [2]. Always confirm fasting status.
• Acute hepatitis flare or ALT elevation above 5x the upper limit of normal. Hepatocellular inflammation increases tissue stiffness independent of fibrosis [11].
• Congestive hepatopathy from right-sided heart failure. Hepatic venous congestion stiffens the liver parenchyma.
• Heavy alcohol intake within 48 hours. Even a single binge episode can transiently raise LSM.
• Cholestasis with bilirubin above 5 mg/dL.

Technical failures:

• BMI above 40 kg/m². The standard M probe has a failure rate of 16 to 20% in class III obesity [12]. The XL probe reduces failures to about 5%, though diagnostic accuracy drops slightly.
• Narrow intercostal spaces. Patients with small body habitus may have inadequate acoustic windows.
• Ascites. Free fluid absorbs the shear wave, making measurement impossible.

If the IQR/median ratio exceeds 30% or the success rate drops below 60%, the result is unreliable and should not guide clinical decisions [2]. In these cases, MRI-based proton density fat fraction (MRI-PDFF) for steatosis or MR elastography (MRE) for fibrosis serves as the next step.

FibroScan vs. MR Elastography: Which Test and When?

VCTE is the right first-line test for most patients. It costs roughly $150 to $350 out of pocket (Medicare and most commercial payers cover it with appropriate ICD-10 coding), takes 10 minutes, and requires no appointment at an imaging center. MRE costs $800 to $1,500, requires a 30- to 45-minute MRI session, and has limited availability.

Where MRE wins: diagnostic accuracy. A 2023 head-to-head meta-analysis in Clinical Gastroenterology and Hepatology (N=2,116) found MRE had an AUROC of 0.93 for F≥2 vs. 0.87 for VCTE [13]. MRE also performs better in obese patients and provides a whole-liver stiffness map rather than a single-point measurement.

"We reserve MRE for patients in whom VCTE is technically inadequate or when the clinical stakes of misclassification are highest, such as transplant evaluation or clinical trial enrollment," states the AGA 2023 Clinical Practice Update [4].

For routine MASLD surveillance, post-treatment monitoring, and initial fibrosis screening, VCTE remains the practical choice. Reserve MRE for discordant results, VCTE technical failures, or situations where precise fibrosis staging changes a treatment decision (e.g., resmetirom eligibility in a borderline case).

FibroScan and Resmetirom (Rezdiffra): The MASLD Treatment Connection

The FDA's March 2024 accelerated approval of resmetirom (Rezdiffra) for non-cirrhotic MASH with F2-F3 fibrosis created direct clinical demand for FibroScan. Before prescribing resmetirom, clinicians need documented evidence of fibrosis stage.

In the MAESTRO-NASH trial (N=966), resmetirom 100 mg daily achieved MASH resolution without worsening of fibrosis in 25.9% of patients at 52 weeks vs. 9.7% with placebo (P<0.001) [14]. A ≥1-stage fibrosis improvement occurred in 24.2% vs. 14.2% with placebo [14]. Participants were staged using a combination of liver biopsy and non-invasive tests at screening.

In practice, many hepatologists and endocrinologists now use VCTE as the initial gatekeeper: if LSM falls between 8.0 and 13.5 kPa in a patient with metabolic risk factors and elevated ALT, the clinical picture supports F2-F3 MASH. Some prescribers still require confirmatory biopsy, but the trend is moving toward NIT-based prescribing as real-world data accumulate.

AACE's 2022 Clinical Practice Guideline for MASLD explicitly endorses VCTE-based staging as sufficient for treatment decisions in most patients, noting that "liver biopsy should be reserved for cases where non-invasive testing yields discordant or indeterminate results" [15].

How to Lower an Elevated FibroScan Score

An elevated FibroScan reading reflects liver stiffness, which in MASLD is driven by fibrosis, inflammation, and steatosis. Reducing any of these components can lower the score over time.

Weight loss remains the most effective intervention. In the Cuban NAFLD cohort study (N=293), patients who achieved ≥10% total body weight loss showed a mean LSM reduction of 3.6 kPa over 52 weeks, and 63% had histologic fibrosis regression by ≥1 stage [16]. Even 5 to 7% weight loss can reduce CAP scores and hepatic inflammation.

GLP-1 receptor agonists show promise. In a 72-week substudy of the LEAN trial, liraglutide 1.8 mg daily reduced LSM by a mean of 2.1 kPa compared with 0.4 kPa in the placebo arm [17]. Semaglutide data from STEP-associated liver substudies show similar directional benefit, though dedicated VCTE endpoint trials are ongoing.

Resmetirom lowers LSM as a downstream effect of MASH resolution. In MAESTRO-NASH, the treatment arm showed a mean 1.8 kPa reduction in liver stiffness at 52 weeks [14].

Alcohol cessation in ALD-related elevations produces measurable LSM drops within 3 to 6 months. A French prospective study (N=79) showed a mean LSM decline of 28% after 6 months of abstinence [18].

Repeat testing timeline: Recheck VCTE at 6 to 12 months after initiating lifestyle or pharmacologic intervention. Changes in LSM of less than 20% may reflect measurement variability rather than true biologic change [2].

Practical Ordering Guide: CPT Codes, Preparation, and Follow-Up

CPT code: 91200 (liver elastography, mechanical/vibration-based). This code covers both the stiffness measurement and the CAP score when performed on the same visit.

Patient preparation instructions:

• Fast for at least 2 hours (3 hours preferred).
• Avoid alcohol for 48 hours before the exam.
• Wear loose-fitting clothing (the probe contacts skin over the right rib cage).
• No need to hold medications.

Ordering context: Include the clinical indication (MASLD staging, viral hepatitis monitoring, ALD assessment) and relevant lab values (ALT, AST, platelet count, FIB-4 score) to help the interpreting clinician contextualize results.

Follow-up algorithm based on results:

• LSM <8.0 kPa with normal CAP: reassure, recheck in 2 to 3 years if risk factors persist.
• LSM <8.0 kPa with elevated CAP (≥260 dB/m): steatosis without significant fibrosis. Initiate lifestyle intervention, consider GLP-1 RA if concurrent obesity/T2D, recheck in 12 months.
• LSM 8.0 to 13.5 kPa: likely F2-F3. Refer to hepatology. Evaluate for resmetirom candidacy. Repeat VCTE in 6 to 12 months to track trajectory.
• LSM ≥13.6 kPa: probable cirrhosis. Refer to hepatology urgently. Initiate hepatocellular carcinoma surveillance with ultrasound every 6 months. Evaluate for varices screening.

According to AASLD, patients with LSM ≥20 kPa should be considered to have clinically significant portal hypertension and may benefit from non-selective beta-blocker prophylaxis without requiring endoscopic confirmation [3].